Suicidal gene therapy in an NF-B-controlled tumor environment as monitored by a secreted blood reporter

Gene Therapy

Volumn 18, Issue 5, 2011, Pages 445-451

  Badr, C E ^a,b,c   Niers, J M ^a,b,c   Morse, D ^a,b   Koelen, J A ^a,b,d   Vandertop, P ^c   Noske, D ^c   Wurdinger, T ^c   Zalloua, P A ^e   Tannous, B A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e LEBANESE AMERICAN UNIVERSITY   (Lebanon)

Author keywords

blood reporter; cytosine deaminase; Gaussia luciferase; nuclear factor B; Suicidal gene therapy; uracil phosphoribosyltransferase

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; MESSENGER RNA; PRODRUG; TUMOR NECROSIS FACTOR ALPHA; URACIL PHOSPHORIBOSYLTRANSFERASE;

ARTICLE; ASTROCYTOMA; BLOOD; CANCER GENE THERAPY; CANCER THERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG SENSITIVITY; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; LUNG CANCER; MELANOMA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REPORTER GENE; SUICIDE GENE; SUICIDE GENE THERAPY; TRANSGENE; TUMOR CELL; TUMOR XENOGRAFT; YEAST;

ANIMALS; CELL LINE, TUMOR; ENZYME ACTIVATION; FLUCYTOSINE; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; HUMANS; LENTIVIRUS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NF-KAPPA B; PROMOTER REGIONS, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955942242     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.156     Document Type: Article

References (52)

1. Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 2000; 60: 5359-5364.
2. Lidor YJ, Lee WE, Nilson JH, Maxwell IH, Su LJ, Brand E et al. In vitro expression of the diphtheria toxin A-chain gene under the control of human chorionic gonadotropin gene promoters as a means of directing toxicity to ovarian cancer cell lines. Am J Obstet Gynecol 1997; 177: 579-585. (Pubitemid 27413772)
3. Mueller H. Tumor necrosis factor as an antineoplastic agent: pitfalls and promises. Cell Mol Life Sci 1998; 54: 1291-1298. (Pubitemid 29015292)
4. King GD, Curtin JF, Candolfi M, Kroeger K, Lowenstein PR, Castro MG. Gene therapy and targeted toxins for glioma. Curr Gene Ther 2005; 5: 535-557. (Pubitemid 43009500)
5. Both GW. Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment. Curr Opin Mol Ther 2009; 11: 421-432.
6. Connors TA. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Therapy 1995; 2: 702-709. (Pubitemid 26046568)
7. Denny WA. Prodrugs for gene-directed enzyme-prodrug therapy (suicide Gene therapy). J Biomed Biotechnol 2003; 2003: 48-70. (Pubitemid 36828274)
8. Khatri A, Russell PJ. Targeted, gene-directed enzyme prodrug therapies to tackle diversity and aggression of late stage prostate cancer. Discov Med 2007; 7: 39-45.
9. Moolten FL, Wells JM, Heyman RA, Evans RM. Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum Gene Ther 1990; 1: 125-134. (Pubitemid 120034723)
10. Dilber MS, Abedi MR, Christensson B, Bjorkstrand B, Kidder GM, Naus CC et al. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res 1997; 57: 1523-1528. (Pubitemid 27175570)
11. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 1996; 93: 1831-1835. (Pubitemid 26079840)
12. Hirschowitz EA, Ohwada A, Pascal WR, Russi TJ, Crystal RG. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 1995; 6: 1055-1063.
13. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 1992; 89: 33-37.
14. Rowley S, Lindauer M, Gebert JF, Haberkorn U, Oberdorfer F, Moebius U et al. Cytosine deaminase gene as a potential tool for the genetic therapy of colorectal cancer. J Surg Oncol 1996; 61: 42-48. (Pubitemid 26025127)
15. Gusella M, Frigo AC, Bolzonella C, Marinelli R, Barile C, Bononi A et al. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br J Cancer 2009; 100: 1549-1557.
16. Andersen PS, Smith JM, Mygind B. Characterization of the upp gene encoding uracil phosphoribosyltransferase of Escherichia coli K12. Eur J Biochem 1992; 204: 51-56.
17. Adachi Y, Tamiya T, Ichikawa T, Terada K, Ono Y, Matsumoto K et al. Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine. Hum Gene Ther 2000; 11: 77-89. (Pubitemid 30044042)
18. Hamstra DA, Rice DJ, Fahmy S, Ross BD, Rehemtulla A. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum Gene Ther 1999; 10: 1993-2003. (Pubitemid 29387913)
19. Kievit E, Bershad E, Ng E, Sethna P, Dev I, Lawrence TS et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xeno-grafts. Cancer Res 1999; 59: 1417-1421. (Pubitemid 29160102)
20. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009; 8: 33-40.
21. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-466. (Pubitemid 39329586)
22. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-759. (Pubitemid 41400849)
23. Brach MA, Hass R, Sherman ML, Gunji H, Weichselbaum R, Kufe D. Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J Clin Invest 1991; 88: 691-695.
24. Greenberg H, Ye X, Wilson D, Htoo AK, Hendersen T, Liu SF. Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo. Biochem Biophys Res Commun 2006; 343: 591-596.
25. Dachs GU, Dougherty GJ, Stratford IJ, Chaplin DJ. Targeting gene therapy to cancer: a review. Oncol Res 1997; 9: 313-325. (Pubitemid 127825985)
26. Badr CE, Niers JM, Tjon-Kon-Fat LA, Noske DP, Wurdinger T, Tannous BA. Real-time monitoring of nuclear factor kappaB activity in cultured cells and in animal models. Mol Imaging 2009; 8: 278-290.
27. Tannous BA. Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat Protoc 2009; 4: 582-591.
28. Wurdinger T, Badr C, Pike L, de Kleine R, Weissleder R, Breakefield XO et al. A secreted luciferase for ex vivo monitoring of in vivo processes. Nat Methods 2008; 5: 171-173. (Pubitemid 351181745)
29. Guo RX, Qiao YH, Zhou Y, Li LX, Shi HR, Chen KS. Increased staining for phosphory-lated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol Int 2008; 58: 749-756.
30. Korkolopoulou P, Levidou G, Saetta AA, El-Habr E, Eftichiadis C, Demenagas P et al. Expression of nuclear factor-kappaB in human astrocytomas: relation to pI kappa Ba, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival. Hum Pathol 2008; 39: 1143-1152.
31. McNulty SE, del Rosario R, Cen D, Meyskens Jr FL, Yang S. Comparative expres-sion of NFkappaB proteins in melanocytes of normal skin vs benign intradermal naevus and human metastatic melanoma biopsies. Pigment Cell Res 2004; 17: 173-180. (Pubitemid 38419645)
32. Shukla S, MacLennan GT, Fu P, Patel J, Marengo SR, Resnick MI et al. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 2004; 6: 390-400. (Pubitemid 38924854)
33. Smith D, Shimamura T, Barbera S, Bejcek BE. NF-kappaB controls growth of glioblastomas/astrocytomas. Mol Cell Biochem 2008; 307: 141-147.
34. Zhang Z, Ma J, Li N, Sun N, Wang C. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer. Ann Thorac Surg 2006; 82: 243-248.
35. Yu M, Han J, Cui P, Dai M, Li H, Zhang J et al. Cisplatin up-regulates ICAM-1 expression in endothelial cell via a NF-kappaB dependent pathway. Cancer Sci 2008; 99: 391-397. (Pubitemid 351228497)
36. Das KC, White CW. Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J Biol Chem 1997; 272: 14914-14920. (Pubitemid 27251763)
37. Hwang S, Ding A. Activation of NF-kappa B in murine macrophages by taxol. Cancer Biochem Biophys 1995; 14: 265-272.
38. Hernández-Vargas H, Rodŕiguez-Pinilla SM, Julián-Tendero M, Sánchez-Rovira P, Cuevas C, Antón A et al. Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat 2007; 102: 157-172. (Pubitemid 46452170)
39. Bessho A, Ueoka H, Kiura K, Tabata M, Sunami K, Katayama Y et al. High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer. Anticancer Res 1999; 19: 693-698. (Pubitemid 29168317)
40. Hampl J, Brown A, Rainov N, Breakefield XO. Methods for gene delivery to neural tissue. In: Chin HR, Moldin SO (eds), Methods in Genomic Neuroscience. CRC Press: Baton Rouge, FL, 2001, pp 229-265.
41. Dong Y, Wen P, Manome Y, Parr M, Hirshowitz A, Chen L et al. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum Gene Ther 1996; 7: 713-720.
42. Shah K, Jacobs A, Breakefield XO, Weissleder R. Molecular imaging of gene therapy for cancer. Gene Therapy 2004; 11: 1175-1187. (Pubitemid 39136781)
43. Briat A, Vassaux G. Preclinical applications of imaging for cancer gene therapy. Expert Rev Mol Med 2006; 8: 1-19. (Pubitemid 44070081)
44. Contag CH, Ross BD. It's not just about anatomy: in vivo bioluminescence imaging as an eyepiece into biology. J Magn Reson Imaging 2002; 16: 378-387. (Pubitemid 35167873)
45. Gross S, Piwnica-Worms D. Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell 2005; 7: 5-15. (Pubitemid 40126378)
46. Min JJ, Gambhir SS. Gene therapy progress and prospects: noninvasive imaging of gene therapy in living subjects. Gene Therapy 2004; 11: 115-125. (Pubitemid 38159683)
47. Xing L, Deng X, Kotedia K, Ackerstaff E, Ponomarev V, Clifton Ling C et al. Non-invasive molecular and functional imaging of cytosine deaminase and uracil phosphoribosyl-transferase fused with red fluorescence protein. Acta Oncol 2008; 47: 1211-1220.
48. Weissleder R. A clearer vision for in vivo imaging. Nat Biotechnol 2001; 19: 316-317.
49. Martuza RL, Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med 1988; 318: 684-688.
50. Chung JH, Whiteley M, Felsenfeld G. A 5¢ element of the chicken beta-globin domain serves as an insulator in human erythroid acells and protects against position effect in Drosophila. Cell 1993; 74: 505-514. (Pubitemid 23244616)
51. Tannous BA, Kim DE, Fernandez JL, Weissleder R, Breakefield XO. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther 2005; 11: 435-443. (Pubitemid 40277320)
52. Sena-Esteves M, Tebbets JC, Steffens S, Crombleholme T, Flake AW. Optimized large-scale production of high titer lentivirus vector pseudotypes. J Virol Methods 2004; 122: 131-139. (Pubitemid 39470183)